N/A N=134 Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)
Bradycardia
Primary: Percentage of Intrinsic Ventricular Events — 82.7; 22.8 % of intrinsic ventricular events — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=16 Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Tachycardia, Ventricular
Primary: Inhibition of Idiopathic Ventricular Tachycardia
Phase 4 N=605 PreFER Managed Ventricular Pacing (MVP) For Elective Replacement
Cardiovascular Diseases
Primary: Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant — 43; 40 number of participants — p=0.72
N/A N=14 Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic Polymorphic Ventricular Tachycardia
Primary: Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing — 2; 9 Participants — p=0.008
N/A N=145 Bipolar Ventricular Tachycardia (VT) Study
Ventricular Tachycardia
Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants
Phase 2 N=6 Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Ventricular Premature Complexes · Myocardial Ischemia
Primary: The Effect of Ranolazine on the PVC Burden Over 30 Days — 5.71; 5.495 percentage of PVC burden
Phase 2 N=19 Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia
Ventricular Tachycardia · Cardiomyopathy · Premature Ventricular Contractions
Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=22 InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's
Heart Diseases · Left Ventricular Dysfunction
Primary: Peak Vo2 — 33; 12.5 ml/kg/min
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
N/A N=20 EGM Analysis in Idiopathic Outflow Tract Ventricular Arrhythmia
Ventricular Outflow Tract Tachycardia
Primary: Percent of Ablation Targets With Termination of the Clinical Ventricular Arrhythmia After RF Energy Delivery — 20 Participants
Phase 2 N=22 Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
N/A N=180 Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial
Ventricular Tachycardia (VT)
Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants
N/A N=10 Ablation at Virtual-hEart pRedicted Targets for VT
Ventricular Tachycardia · Ischemic Cardiomyopathy
Primary: Number of Participants With Ventricular Tachycardia Inducibility — 6 Participants
N/A N=101 Automated Assessment of PVI Using a Novel EP Recording System
Paroxysmal Atrial Fibrillation · Persistent Atrial Fibrillation
Primary: PVI Analyzer Sensitivity and Specificity, Measured as the Accuracy of Predictions for Non-isolated and Isolated Veins. — 216; 215 Electrogram (EGM) — p=0.006
Phase 2 N=69 ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Atrial Fibrillation
Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001
N/A N=240 PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
Left Ventricular Dysfunction
Primary: Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort). — -2.29; -3.43 percentage — p=0.4347
N/A N=40 Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Tachycardia, Ventricular
Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
Phase 4 N=53 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
N/A N=6 Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Catecholaminergic Polymorphic Ventricular Tachycardia
Primary: Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery) — 46; 0 number of ventricular beats
Phase 4 N=1,166 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure
Atrial Fibrillation · Heart Failure, Congestive
Primary: Composite Endpoint Composed by Death for Any Cause, Cardiovascular Hospitalization or Permanent AF at 2 Years — 28.0; 23.1; 21.5 percentage of participants
N/A N=242 The IPED (Investigation of Palpitations in the ED) Study
Presyncope · Arrhythmias, Cardiac · Tachycardia, Supraventricular
Primary: Number of Participants With Symptomatic Rhythm Detection up to 90 Days — 69; 11 Participants
Phase 4 N=100 The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock
Ventricular Tachycardia · Ventricular Fibrillation · Atrial Fibrillation
Primary: Number of Subjects Inappropriately Shocked by Implantable Cardioverter-Defibrillator (ICD) — 1; 1 Participants — p=1.0
N/A N=1,833 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization
Atrioventricular Block · Ventricular Dysfunction
Primary: Total Mortality — 307; 305 Participants — p=0.3492
Phase 4 N=925 ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec) — 64.9; 69.7 Percentage of FVT episodes…